|
|
Recent Articles
-
Vertex Pharma to Acquire Alpine Immune Services
Apr 13, 2024
-
Image: Vertex Pharma’s shares have had a nice run the past couple years.
On April 10, Vertex Pharma announced that it had entered into an agreement where Vertex will acquire Alpine Immune Services for $65 per share or ~$4.9 billion in cash. We have no qualms with the deal for Alpine, and we expect Vertex Pharma to continue to deliver for shareholders.
-
JPMorgan Cautious on Geopolitical Tensions and Inflationary Pressures
Apr 12, 2024
-
Image Source: Hakan Dahlstrom.
On April 12, JPMorgan reported mixed first-quarter 2024 results. JPMorgan is one of our favorite banks, in part due to strong leadership at the top and solid fortress-like balance sheet. Though we don’t include any individual bank in the newsletter portfolios, we do think the Financial Select Sector SPDR makes sense for diversification reasons, as showcased in the Best Ideas Newsletter portfolio. Shares of JPMorgan yield ~2.4% at the time of this writing.
-
Dividend Increases/Decreases for the Week of April 12
Apr 12, 2024
-
Let's take a look at firms raising/lowering their dividends this week.
-
Fastenal Puts Up Mixed First Quarter Results
Apr 11, 2024
-
Image: Fastenal reported mixed first quarter 2024 results. We like its business model quite a bit.
On April 11, Fastenal Company reported mixed first-quarter fiscal 2024 results with revenue and earnings per share coming in slightly lower than expectations. Net sales advanced 1.9% for the three-month period ending March 31. The company noted that adverse weather impacted sales in its first quarter by about 10 to 30 basis points on a net basis. Operating income nudged lower in the quarter modestly, while net income advanced 0.9% in the period on a year-over-year basis. Diluted earnings per share was roughly flat in the quarter on a year-over-year basis, increasing 0.6% from the same period a year ago. We like Fastenal’s business model quite a bit, and shares yield ~2.1% at the time of this writing.
|
